| 1 |
Alonso-Castro S, García-Valle A, Morante-Bolado I, Braña I, Pardo E, Queiro R. Differentiated Effect of Smoking on Disease Activity and Quality of Life among Different Spondyloarthritis Phenotypes. J Clin Med 2023;12. [PMID: 36675480 DOI: 10.3390/jcm12020551] [Reference Citation Analysis]
|
| 2 |
Kleinrensink NJ, Perton FT, Pouw JN, Vincken NLA, Hartgring SAY, Jansen MP, Arbabi S, Foppen W, de Jong PA, Tekstra J, Leijten EFA, Spierings J, Lafeber FPJG, Welsing PMJ, Heijstek MW; TOFA-PREDICT author group. TOFA-PREDICT study protocol: a stratification trial to determine key immunological factors predicting tofacitinib efficacy and drug-free remission in psoriatic arthritis (PsA). BMJ Open 2022;12:e064338. [PMID: 36216430 DOI: 10.1136/bmjopen-2022-064338] [Reference Citation Analysis]
|
| 3 |
Barbarroja N, Ruiz-ponce M, Cuesta-lópez L, Pérez-sánchez C, López-pedrera C, Arias-de la Rosa I, Collantes-estévez E. Nonalcoholic fatty liver disease in inflammatory arthritis: Relationship with cardiovascular risk. Front Immunol 2022;13:997270. [DOI: 10.3389/fimmu.2022.997270] [Reference Citation Analysis]
|
| 4 |
Li B, Su R, Yan H, Liu J, Gao C, Li X, Wang C. Immunological risk factors for nonalcoholic fatty liver disease in patients with psoriatic arthritis: New predictive nomograms and natural killer cells. Front Immunol 2022;13:907729. [DOI: 10.3389/fimmu.2022.907729] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 5 |
D'Angelo S, Salvarani C, Marando F, Gualberti G, Novelli L, Curradi G, Tripepi G, Pitino A, Ramonda R, Marchesoni A. Residual Disease in Patients with Axial Spondyloarthritis: A Post-Hoc Analysis of the QUASAR Study. J Clin Med 2022;11. [PMID: 35743623 DOI: 10.3390/jcm11123553] [Reference Citation Analysis]
|
| 6 |
Novelli L, Lubrano E, Venerito V, Perrotta FM, Marando F, Curradi G, Iannone F. Extra-Articular Manifestations and Comorbidities in Psoriatic Disease: A Journey Into the Immunologic Crosstalk. Front Med (Lausanne) 2021;8:737079. [PMID: 34631754 DOI: 10.3389/fmed.2021.737079] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Zabotti A, Luchetti MM, Selmi CF, Ramonda R, Grembiale RD, Dagna L, D'Angelo S, Cafaro G, De Vita S, Felicetti M, Marelli S, Frigerio D, Favalli EG. An Italian Disease-Based Registry of Axial and Peripheral Spondyloarthritis: The SIRENA Study. Front Med (Lausanne) 2021;8:711875. [PMID: 34631733 DOI: 10.3389/fmed.2021.711875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Abbasi-Perez A, Alvarez-Mon MA, Donat-Vargas C, Ortega MA, Monserrat J, Perez-Gomez A, Sanz I, Alvarez-Mon M. Analysis of Tweets Containing Information Related to Rheumatological Diseases on Twitter. Int J Environ Res Public Health 2021;18:9094. [PMID: 34501681 DOI: 10.3390/ijerph18179094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 9 |
Chimenti MS, Conigliaro P, Caso F, Costa L, Ortolan A, Triggianese P, Tasso M, Fonti GL, Lorenzin MG, Perricone R, Ramonda R. Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement. Clin Rheumatol 2021. [PMID: 34410550 DOI: 10.1007/s10067-021-05874-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 10 |
Chu BBR, Pereira da Cunha JPVV, Marcon JMT, de Arruda Prado LE, Rosa FLS, Leitão JM, Thomaz AC, Kowalski SC, Azevedo VF. Does Disease Activity Influence the Levels of Uric Acid in Psoriatic Arthritis? TORJ 2021;15:57-64. [DOI: 10.2174/1874312902115010057] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 11 |
Expósito MV, Tinedo MT, Cáceres BB, Corral JB, Martínez MR. Espondiloartritis. Medicine - Programa de Formación Médica Continuada Acreditado 2021;13:1599-1610. [DOI: 10.1016/j.med.2021.03.018] [Reference Citation Analysis]
|
| 12 |
Brüner M, Dige A, Loft AG, Laurberg TB, Agnholt JS, Clemmensen K, McInnes I, Lories R, Iversen L, Hjuler KF, Kragstrup TW. Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment. Autoimmun Rev 2021;20:102731. [PMID: 33326852 DOI: 10.1016/j.autrev.2020.102731] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 13 |
Lubrano E, Scriffignano S, Perrotta FM. Multimorbidity and comorbidity in psoriatic arthritis - a perspective. Expert Rev Clin Immunol 2020;16:963-72. [PMID: 32940114 DOI: 10.1080/1744666X.2021.1825941] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 14 |
Zagni E, Colombo D, Fiocchi M, Perrone V, Sangiorgi D, Andretta M, De Sarro G, Nava E, Degli Esposti L. Pharmaco-utilization of biologic drugs in patients affected by psoriasis, psoriatic arthritis and ankylosing spondylitis in an Italian real-world setting. Expert Review of Pharmacoeconomics & Outcomes Research 2020;20:491-7. [DOI: 10.1080/14737167.2020.1800456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 15 |
Lubrano E, Scriffignano S, Azuaga AB, Ramirez J, Cañete JD, Perrotta FM. Impact of Comorbidities on Disease Activity, Patient Global Assessment, and Function in Psoriatic Arthritis: A Cross-Sectional Study. Rheumatol Ther 2020;7:825-36. [PMID: 32804332 DOI: 10.1007/s40744-020-00229-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 16 |
Rahman P, Arendse R, Khraishi M, Sholter D, Sheriff M, Rampakakis E, Lehman AJ, Nantel F. Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry. BMJ Open 2020;10:e036245. [PMID: 32792436 DOI: 10.1136/bmjopen-2019-036245] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 17 |
Chimenti MS, Perricone C, Conigliaro P, Triggianese P, D'Antonio A, de Martino E, Fonti GL, Caso F, Costa L, Perricone R. Tackling the autoimmune side in Spondyloarthritis: A systematic review. Autoimmun Rev 2020;19:102648. [PMID: 32801035 DOI: 10.1016/j.autrev.2020.102648] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 18 |
Cañete JD, Tasende JAP, Laserna FJR, Castro SG, Queiro R. The Impact of Comorbidity on Patient-Reported Outcomes in Psoriatic Arthritis: A Systematic Literature Review. Rheumatol Ther 2020;7:237-57. [PMID: 32270447 DOI: 10.1007/s40744-020-00202-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 19 |
Lubrano E, Scriffignano S, Perrotta FM. TNF-alpha inhibitors for the six treatment targets of psoriatic arthritis. Expert Rev Clin Immunol 2019;15:1303-12. [PMID: 31652079 DOI: 10.1080/1744666X.2020.1685382] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 20 |
Hong C, Kwan YH, Leung YY, Lui NL, Fong W. Comparison of ankylosing spondylitis and non-radiographic axial spondyloarthritis in a multi-ethnic Asian population of Singapore. Int J Rheum Dis 2019;22:1506-11. [PMID: 31090201 DOI: 10.1111/1756-185X.13603] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
|
